Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GZ 17-6.02

Next Previous
Drug Profile

GZ 17-6.02

Alternative Names: GZ17-6.02; GZ21-T

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzada Pharmaceuticals
  • Class Antineoplastics; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Actinic keratosis; Lymphoma; Solid tumours

Most Recent Events

  • 28 Mar 2025 GZ 17-6.02 is still in phase I development for Lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Genzada Pharmaceuticals Pipeline, March 2025)
  • 28 Mar 2025 GZ 17-6.02 is still in phase I development for Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (Genzada Pharmaceuticals Pipeline, March 2025)
  • 16 Oct 2024 Genzada Pharmaceuticals plans a phase I trial for Prostate cancer (Hormone refractory, Late-stage disease, Second-line therapy or greater) in USA in October 2024 (PO) (NCT06636123)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top